Department of Medicine
Faculty Profiles by Division

Division of Infectious Diseases

Faculty Profiles

[Return To Index page]
photo Erin K. McCreary, PharmD, BCPS, BCIDP

Infectious Diseases

Clinical Assistant Professor of Medicine

Director of Infectious Diseases Improvement and Clinical Research Innovation, UPMC


Office: Forbes Tower
3600 Forbes Ave, Suite 7125
Pittsburgh, PA 15213
Education and Training
Doctor of Pharmacy, Auburn University Harrison School of Pharmacy, 2015
Bachelor of Science in Biomedical Sciences, Auburn University College of Science and Mathematics, 2011
PGY2 Infectious Diseases Specialty Resident, University of Wisconsin Health, 2017
PGY1 Pharmacy Resident, University of Wisconsin Health, 2016
Research Interest
Dr. McCreary’s primary research interests focus on a “bench to bedside” approach of optimizing pharmacokinetic and pharmacodynamic principles for antimicrobial utilization and translational antibiotic stewardship initiatives. In less than 18 months at UPMC, she led and implemented stewardship initiatives including: dose-optimization of anti-pseudomonal beta-lactam antibiotics, comprehensive antimicrobial dosing chart by indication, transplant prophylaxis guideline updates, novel necrotizing skin and soft tissue infection pathway, evaluation and assessment of beta-lactam allergy pathway, vancomycin area-under-the-curve-based dosing pharmacokinetic service, and antifungal stewardship.
Clinical Interest
Dr. McCreary is a pharmacist who serves as the Chair of the UPMC System COVID-19 Therapeutics Committee. She also engages in tele-stewardship with several communities hospitals and rounds with the Presbyterian Shadyside infectious diseases consult services. She specializes in the management of patients infected by drug-resistant and/or fungal pathogens.
Educational Interest
Dr. McCreary lectures in the School of Medicine, providing education on antimicrobial agents, pharmacokinetics/pharmacodynamics, and the rationale use of antibiotics. She also provides mentorship for medical and pharmacy trainees pursing clinical and translational research.
For my complete bibliography, Click Here.
Selected Publications:
McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. JAMA. 2020; 324(11): 1041-1042.
McCreary EK, Meyer NJ. Coronavirus disease 2019 controversies: the tocilizumab chapter. British Medical Association. 2021; 372: 244.
Seymour CW, McCreary EK, Stegenga J. Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic. JAMA. 2020.
Schwartz IS, Heil EL, McCreary EK. Remdesivir: a pendulum in a pandemic. British Medical Association. 2020; 371: 4560.
McCreary EK, Byers K, Fernandes C, Kline E, Nicolau DP, Shields RK. Plasma and cerebrospinal fluid therapeutic drug monitoring of ceftolozane and tazobactam during treatment of pan-ß-lactam-resistant Pseudomonas aeruginosa meningitis. Open Forum Infectious Disease. 2020; 7(12): 549.
UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021; 22(1): 100.
McCreary EK, Nguyen MH, Davis MR, Borlagdan J, Shields RK, Anderson AD, Rivosecchi RM, Marini RV, Sacha LM, Silveira FP, Andes DR, Lepak AJ. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. The Journal of Antimicrobial Chemotherapy. 2020; 75(10): 3023-3028.
Davis MR, McCreary EK, Pogue JM. That Escalated Quickly: Remdesivir’s Place In Therapy for COVID-19. Infectious Diseases and Therapy. 2020; 9(3): 525-536.
McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases. 2019; 7(4): 105.
McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, Ouellette K, Vasina L, Haddad F, Rybak MJ, Zervos MJ, Sakoulas G, Rose WE. Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. Open Forum Infectious Diseases. 2019; 7(1): 538.
Notable Achievements
Auburn University Young Alumni Achievement Award, 2022
IDSA Clinical Practice Innovation Award, 2022
ACCP Infectious Diseases Practice and Research Network New Practitioner Award, 2022
UPMC Award for Commitment and Excellence in Service (ACES), 2021
Distinguished Alumnus - Auburn University Rho Chi Chapter, 2021
First Place in Innovation - UPMC Quality and Safety Fair 2020, 2020
Society of Infectious Diseases Pharmacists Executive Board Member, 2020-2022
Congressional Citizenship Award, 2008
Congressional Citizenship Award, 2008